NEOG Quote, Financials, Valuation and Earnings

Amgen, Inc. has a net margin of -7.09% compared to Neogen Corp.'s net margin of 13.51%. Neogen Corp.'s return on equity of -25.93% beat Amgen, Inc.'s return on equity of 102.03%.

Neogen Corp. has a consensus price target of $11.67, signalling upside risk potential of 8.03%. On the other hand Amgen, Inc. has an analysts' consensus of $341.93 which suggests that it could fall by -11.03%. Given that Neogen Corp. has higher upside potential than Amgen, Inc., analysts believe Neogen Corp. is more attractive than Amgen, Inc..

Neogen Corp. has a beta of 1.980, which suggesting that the stock is 98.002% more volatile than S&P 500. In comparison Amgen, Inc. has a beta of 0.465, suggesting its less volatile than the S&P 500 by 53.492%.

Neogen Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amgen, Inc. offers a yield of 2.48% to investors and pays a quarterly dividend of $2.38 per share. Neogen Corp. pays -- of its earnings as a dividend. Amgen, Inc. pays out 66.9% of its earnings as a dividend. Amgen, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Neogen Corp. quarterly revenues are $224.7M, which are smaller than Amgen, Inc. quarterly revenues of $9.9B. Neogen Corp.'s net income of -$15.9M is lower than Amgen, Inc.'s net income of $1.3B. Notably, Neogen Corp.'s price-to-earnings ratio is 2,124.15x while Amgen, Inc.'s PE ratio is 27.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neogen Corp. is 2.66x versus 5.67x for Amgen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of -7.09% compared to Neogen Corp.'s net margin of 20.83%. Neogen Corp.'s return on equity of -25.93% beat Johnson & Johnson's return on equity of 33.27%.

Neogen Corp. has a consensus price target of $11.67, signalling upside risk potential of 8.03%. On the other hand Johnson & Johnson has an analysts' consensus of $230.63 which suggests that it could fall by -3.9%. Given that Neogen Corp. has higher upside potential than Johnson & Johnson, analysts believe Neogen Corp. is more attractive than Johnson & Johnson.

Neogen Corp. has a beta of 1.980, which suggesting that the stock is 98.002% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.350, suggesting its less volatile than the S&P 500 by 64.977%.

Neogen Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.14% to investors and pays a quarterly dividend of $1.30 per share. Neogen Corp. pays -- of its earnings as a dividend. Johnson & Johnson pays out 46.59% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Neogen Corp. quarterly revenues are $224.7M, which are smaller than Johnson & Johnson quarterly revenues of $24.6B. Neogen Corp.'s net income of -$15.9M is lower than Johnson & Johnson's net income of $5.1B. Notably, Neogen Corp.'s price-to-earnings ratio is 2,124.15x while Johnson & Johnson's PE ratio is 21.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neogen Corp. is 2.66x versus 6.19x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Outlook Therapeutics, Inc. has a net margin of -7.09% compared to Neogen Corp.'s net margin of -1338.77%. Neogen Corp.'s return on equity of -25.93% beat Outlook Therapeutics, Inc.'s return on equity of --.

Neogen Corp. has a consensus price target of $11.67, signalling upside risk potential of 8.03%. On the other hand Outlook Therapeutics, Inc. has an analysts' consensus of $6.83 which suggests that it could grow by 1491.37%. Given that Outlook Therapeutics, Inc. has higher upside potential than Neogen Corp., analysts believe Outlook Therapeutics, Inc. is more attractive than Neogen Corp..

Neogen Corp. has a beta of 1.980, which suggesting that the stock is 98.002% more volatile than S&P 500. In comparison Outlook Therapeutics, Inc. has a beta of 0.102, suggesting its less volatile than the S&P 500 by 89.777%.

Neogen Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Outlook Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neogen Corp. pays -- of its earnings as a dividend. Outlook Therapeutics, Inc. pays out -- of its earnings as a dividend.

Neogen Corp. quarterly revenues are $224.7M, which are larger than Outlook Therapeutics, Inc. quarterly revenues of $1.5M. Neogen Corp.'s net income of -$15.9M is higher than Outlook Therapeutics, Inc.'s net income of -$20.2M. Notably, Neogen Corp.'s price-to-earnings ratio is 2,124.15x while Outlook Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neogen Corp. is 2.66x versus 8.27x for Outlook Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Teleflex, Inc. has a net margin of -7.09% compared to Neogen Corp.'s net margin of -44.78%. Neogen Corp.'s return on equity of -25.93% beat Teleflex, Inc.'s return on equity of -7.84%.

Neogen Corp. has a consensus price target of $11.67, signalling upside risk potential of 8.03%. On the other hand Teleflex, Inc. has an analysts' consensus of $129.25 which suggests that it could grow by 19.21%. Given that Teleflex, Inc. has higher upside potential than Neogen Corp., analysts believe Teleflex, Inc. is more attractive than Neogen Corp..

Neogen Corp. has a beta of 1.980, which suggesting that the stock is 98.002% more volatile than S&P 500. In comparison Teleflex, Inc. has a beta of 0.917, suggesting its less volatile than the S&P 500 by 8.269%.

Neogen Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Teleflex, Inc. offers a yield of 1.25% to investors and pays a quarterly dividend of $0.34 per share. Neogen Corp. pays -- of its earnings as a dividend. Teleflex, Inc. pays out 91.92% of its earnings as a dividend. Teleflex, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Neogen Corp. quarterly revenues are $224.7M, which are smaller than Teleflex, Inc. quarterly revenues of $913M. Neogen Corp.'s net income of -$15.9M is higher than Teleflex, Inc.'s net income of -$408.9M. Notably, Neogen Corp.'s price-to-earnings ratio is 2,124.15x while Teleflex, Inc.'s PE ratio is 25.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neogen Corp. is 2.66x versus 1.54x for Teleflex, Inc.. Usually stocks with elevated PS ratios are considered overvalued.